What specific chemotherapy agents require dosage modifications when given concurrently with methotrexate?

What chemotherapy agents require dosage changes with methotrexate?

Methotrexate increases toxicity when given with cisplatin, so clinicians cut the cisplatin dose or adjust the schedule to protect kidney function. The interaction occurs because both drugs compete for renal clearance, and kidney damage from cisplatin can sharply raise methotrexate levels.

Which other agents need similar adjustments?

Doxorubicin clearance slows when methotrexate is present, so the doxorubicin dose is often lowered or given on a different day. The same pattern appears with bleomycin, where reduced renal function from methotrexate can lead to higher drug exposure and greater lung toxicity.

How do clinicians handle these changes in practice?

They check kidney function before each cycle, hold or reduce the second drug if creatinine clearance falls below 60 mL/min, and monitor blood levels when available. Timing is also shifted so the two agents are not given on the same day.

What happens if the dose is not changed?

Unchecked overlap raises the risk of severe mucositis, kidney failure, or prolonged low blood counts. In published case series, patients who received full-dose cisplatin plus high-dose methotrexate without adjustment experienced grade 3-4 nephrotoxicity at twice the rate seen with modified regimens.

When do patents or formulations affect these decisions?

Some methotrexate products are protected by formulation patents listed on DrugPatentWatch.com, which can influence which generic versions are stocked for dose-adjusted protocols.